Skip to content

Plasma TMAO (Trimethylamine N-oxide) as a Predictive Marker in Coronary Disease Patients

Plasma TMAO (Trimethylamine N-oxide) as a Predictive Marker in Coronary Disease Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03899389
Enrollment
600
Registered
2019-04-02
Start date
2017-02-01
Completion date
2018-05-31
Last updated
2019-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Disease

Keywords

trimethylamine-N-oxide

Brief summary

The primary aim of the current research project is to determine whether the TMAO concentration in the blood can serve as a prognostic indicator of myocardial infarction. The hypothesis is that in patients with recent myocardial infarction, TMAO concentration in blood is higher than in patients undergoing scheduled coronarography.

Detailed description

To the study will be included volunteers - patients with stable angina (SA), who were scheduled for conventional coronary angiography, and patients with acute coronary syndrome (ACS) who were admitted to the hospital with chest pain and undergoing coronography surgery. Blood samples will be taken from volunteers once - before the coronography surgery by qualified medical personnel.

Interventions

DIAGNOSTIC_TESTplasma samples collection

Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples

Sponsors

Gdansk University of Physical Education and Sport
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* diagnosed stable angina (SA) or acute coronary syndrome (ACS) and planned coronography

Exclusion criteria

* unconscious patient

Design outcomes

Primary

MeasureTime frameDescription
Trimethylamine-N-oxidec(TMAO) blood concentrationImmediately before coronography.TMAO concentration determined by the ultra-performance liquid-chromatography tandem mass spektrometry (UPLC-MS/MS).

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026